LTR Pharma Completed Phase II Spontan Clinical Study
The intranasal spray outperformed traditional oral vardenafil tablets in absorption speed during clinical trials.
Updated on Oct. 1, 2026 in Sex Life
Live Poll
Would you consider switching to a faster-acting nasal spray for treating erectile dysfunction?
LTR Pharma has finalized the Phase II clinical report for Spontan, an intranasal erectile dysfunction spray. The study demonstrated that the treatment reaches peak blood concentration significantly faster than standard oral vardenafil tablets.
Why it matters
By achieving faster absorption rates than existing oral medications, Spontan could offer a more efficient treatment option for those seeking faster onset. These results now set the stage for the company to begin regulatory licensing discussions in the United States.
The clinical study of 27 healthy adult males showed Spontan 5mg achieved peak concentration in 10 minutes, compared to 60 minutes for a 20mg oral vardenafil tablet. The 5mg dose also resulted in four-fold lower total exposure.
The players
LTR Pharma
This is a pharmaceutical company that focuses on developing innovative treatments for sexual health disorders.
US Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of human drugs and medical devices.
The details
The randomized, open-label, three-way crossover study included 14 participants aged 65 and over to evaluate efficacy across age demographics. The trial protocol was developed in alignment with US Food and Drug Administration pre-IND guidance to ensure the dataset meets international regulatory standards.
Timeline
The final Phase II clinical report was completed on October 1, 2026.
Culture Shift
This development reflects a broader shift toward optimizing drug delivery systems to improve user convenience and performance. By aligning with the US Food and Drug Administration pre-IND guidance, the research marks a strategic step toward diversifying the landscape of sexual health treatments.
The potential availability of a faster-acting intranasal spray could change how users manage their daily routines by reducing the wait time between dosing and effect. Consumers may see these changes in treatment accessibility if the company successfully navigates the US licensing process.
The takeaway
The study suggests that intranasal delivery can significantly improve the speed of drug absorption compared to traditional tablets. Users should monitor future regulatory updates to see if this delivery method becomes a viable alternative to existing oral medications.
Further reading
For more information on the current landscape of sexual health treatments, visit the Sex Life section.
Source note: This article includes information reported by Small Caps.
Live Poll
Would you consider switching to a faster-acting nasal spray for treating erectile dysfunction?
